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AbstRAct
Objective Colorectal cancer (CRC) leads to significant 
morbidity/mortality worldwide. Defining critical research 
gaps (RG), their prioritisation and resolution, could 
improve patient outcomes.
Design RG analysis was conducted by a 
multidisciplinary panel of patients, clinicians and 
researchers (n=71). Eight working groups (WG) 
were constituted: discovery science; risk; prevention; 
early diagnosis and screening; pathology; curative 
treatment; stage IV disease; and living with 
and beyond CRC. A series of discussions led to 
development of draft papers by each WG, which were 
evaluated by a 20-strong patient panel. A final list of 
RGs and research recommendations (RR) was endorsed 
by all participants.
Results Fifteen critical RGs are summarised below: 
RG1: Lack of realistic models that recapitulate 
tumour/tumour micro/macroenvironment; RG2: 
Insufficient evidence on precise contributions of 
genetic/environmental/lifestyle factors to CRC risk; 
RG3: Pressing need for prevention trials; RG4: Lack 
of integration of different prevention approaches; 
RG5: Lack of optimal strategies for CRC screening; 
RG6: Lack of effective triage systems for invasive 
investigations; RG7: Imprecise pathological assessment 
of CRC; RG8: Lack of qualified personnel in genomics, 
data sciences and digital pathology; RG9: Inadequate 
assessment/communication of risk, benefit and 
uncertainty of treatment choices; RG10: Need for 
novel technologies/interventions to improve curative 
outcomes; RG11: Lack of approaches that recognise 
molecular interplay between metastasising tumours 
and their microenvironment; RG12: Lack of reliable 
biomarkers to guide stage IV treatment; RG13: Need to 
increase understanding of health related quality of life 
(HRQOL) and promote residual symptom resolution; 
RG14: Lack of coordination of CRC research/funding; 
RG15: Lack of effective communication between 
relevant stakeholders.
conclusion Prioritising research activity and funding could 
have a significant impact on reducing CRC disease burden 
over the next 5 years.
IntRODuctIOn
The global burden of colorectal cancer (CRC) is 
rising, with 2.2 million predicted new cases (and 
1.1 million deaths) by 2030.1 In the UK, >41 000 
new cases were diagnosed in 2014, and ~16 000 
people died of the disease.2 Estimates of the global 
economic burden of CRC approach $100 billion;3 
in the USA, medical expenditure alone is predicted 
to rise to >$20 billion by 2020.4 In the UK, total 
economic costs of CRC exceeded £1.6 billion in 
2009.5 
In 2014, the US National Cancer Institute 
(NCI) spent $223 million for CRC research, 
placing it fourth behind breast cancer ($530 
million), lung cancer ($254 million) and 
leukaemia ($237 million).6 Cancer Research UK 
(CRUK) figures indicated that its annual expense 
specifically on CRC research in 2016–2017 was 
£35 million, second behind lung cancer research 
(£43 million) and ahead of breast cancer research 
(£33 million).7 Recognising the need to identify 
current and emerging CRC research gaps (RG) to 
inform research policy and prioritisation, the UK 
charity Bowel Cancer UK (BCUK), aided by the 
UK National Cancer Research Institute (NCRI) 
Colorectal Cancer Clinical Studies Group and The 
Association of Coloproctology of Great Britain 
and Ireland (ACPGBI), drew together health 
professionals, scientists and those affected by 
CRC to identify those research priorities which, 
if addressed, would make the greatest impact on 
lessening global CRC burden.
MethODOlOgy
During 2015–2016, BCUK recruited an all-encom-
passing panel of 71 CRC healthcare professionals 
(HCP), scientists and individuals affected by CRC 
to participate in the BCUK Critical Research Gaps in 
Colorectal Cancer Initiative. The process is outlined 
in figure 1 and reflects previous approaches to iden-
tifying RGs in other diseases.8 A detailed descrip-
tion of the process/methodology is provided in 
online supplementary appendix 1.
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Results
Fifteen critical RGs were identified through the process indi-
cated in figure 1 and described in detail in online supplemen-
tary appendix 1. These RGs are summarised in table 1, and 
the evidence base for the RGs, together with accompanying 
research recommendations (RR), is detailed below in relevant 
thematic areas.
evIDence bAse fOR ReseARch gAPss AnD 
RecOMMenDAtIOns
Discovery science
Current status
Interrogating colorectal biology has revealed important clues to 
key events driving CRC growth, including aberrant Wnt signal-
ling and specific defects in DNA mismatch repair (MMR).9–13 
Gene expression profiling efforts are identifying specific CRC 
molecular subtypes, although their clinical relevance requires 
further elucidation.13–18
Many key areas require further in-depth study. While 
intracancer molecular diversity has been highlighted,16–18 we 
are only starting to understand the greater complexity asso-
ciated with CRC evolution and metastasis.19 Transforming 
growth factor-beta/bone morphogenic protein signalling appears 
important for CRC growth and metastasis,20 but there is scant 
knowledge of the key proteins involved. Other pathways, for 
example, Hippo, and STING, are intriguing players in CRC 
biology, but are currently of uncertain relevance.21 22 The tumour 
micro/macroenvironment, including the microbiome, is largely 
unexplored. Crucially, the dearth of reliable CRC model systems 
is compromising both relevant fundamental research and devel-
opment of novel therapies.
Research Gap (RG1): A need for realistic in silico, in vitro and in 
vivo models that more precisely recapitulate the tumour and its mi-
cro/macroenvironment, to enable comprehensive dissection of the 
relevant mechanisms governing the transition from normal colorec-
tum to the different malignant stages of the disease.
Model systems for CRC research
While cell line models have informed our overall understanding 
of CRC biology, the recognition that they may not represent a 
specific tumour within its particular genetic context and micro-
environment milieu has prompted researchers to develop more 
realistic models that recapitulate different premalignant/malig-
nant stages of CRC. Genetically engineered mouse models,23 for 
example, the ApcMin/+ mouse,24 have allowed interrogation of 
particular disease biology, while the advent of patient-derived 
xenografts has underpinned development of animal models 
representing different stages of human CRC.25 Organoids have 
allowed the 3D structure/microenvironment of the CRC tumour 
to be recreated and manipulated.26 However, as our molecular 
knowledge of CRC expands,13–17 we require models that map 
to distinct disease subtypes, and others that address issues such 
as CRC evolution, intratumoural heterogeneity and treatment 
resistance.
Research Recommendation 1.1 (RR1.1): Develop and share appro-
priate model systems that mimic different premalignant/malignant 
stages of colorectal cancer (CRC), to ensure discovery research 
questions are addressed in the relevant genetic/clinical context.
Investigating CRC signalling pathways and their tractability
Given that pathogenic adenomatous polyposis coli (APC) muta-
tions are rare outside CRC, performing a comprehensive, cell 
type-specific molecular analysis of the normal and APC-mutant 
colorectal crypt would improve understanding of the critical 
pathways/processes underpinning malignant colorectal epithe-
lium development. A concerted Wnt pathway investigation 
programme in normal cells, benign tumours, and primary and 
metastatic CRC (mCRC) tissue is warranted. Challenges include 
development of appropriate quantitative readouts of signalling 
pathways, and novel model systems, perhaps including large 
animal models with greater resemblance to humans. Precise 
elucidation of specific malignant cellular processes could 
underpin identification of novel targets, both for prevention and 
treatment.
RR1.2: Comprehensively interrogate the normal and APC-mutant 
colorectal crypt to reveal differences that may be exploitable for 
CRC prevention/control.
The CRC micro/macroenvironment
We need to consider the role of non-neoplastic cells, particularly 
stromal cells/fibroblasts and immune infiltrates as important arbi-
ters of CRC processes and treatment responses, to better under-
stand the tumour microenvironment and how it is controlled by 
the cancer itself.16–18 Organoid models, or appropriate animal 
figure 1 Bowel Cancer UK Critical Research Gaps in Colorectal 
Cancer Initiative process.
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models encompassing both neoplastic clones and realistic micro-
environments are paramount. Development of in silico systems 
biology platforms that capitalise on these rich data sources 
will allow modelling and deciphering of the complex interplay 
between CRC tumour cells and their microenvironment.
Macroenvironmental effects from gut microbes have been 
implicated in CRC development in experimental animal models, 
but their relevance in humans is less clear. Recent evidence 
published in this journal suggests that altered mucosal micro-
biota are present throughout the colorectum,27 that they have a 
role in regulating the host immune-inflammatory response, and 
may have prognostic relevance for patients with CRC. A deeper 
understanding of the gut microbiome in CRC will also facili-
tate its therapeutic manipulation for improved outcomes in both 
preventative and treatment settings.
RR1.3: Better understand the molecular/cellular interplay between 
the CRC tumour and its microenvironment.
RR1.4: Determine the role of the gut microbiome and how it can 
be exploited to improve CRC disease outcomes.
Risk
Current status
Identifying individuals at increased risk of CRC allows intro-
duction of appropriate screening/surveillance approaches, 
leading to earlier cancer diagnosis and underpinning improved 
survival. However, there is currently an incomplete picture of 
the absolute risk attributable to inherited, environmental or life-
style factors for CRC. Understanding global risk will underpin 
stratified interventions tailored to individual patients for disease 
modification and precision medicine interventions.28
Known Mendelian conditions account for a relatively small 
proportion of inherited risk, with the remainder thought to 
be due to lower penetrance risk factors, including common/
rare genetic variants.29 Approximately 40 common, low pene-
trance CRC risk alleles have been identified.29 Estimations from 
whole-exome sequencing (WES) studies suggest that higher 
penetrance rare variants may additionally account for 16% of 
hereditary risk.30 However, much of the ‘missing heritability’ 
remains unidentified. Additionally, the interaction between 
the microbiome, epigenetics and heritable risk factors remains 
poorly characterised.31
A better understanding of environmental/lifestyle risk factors 
is also required. While associations with diet,32–34 comorbidi-
ties including diabetes35 and aspirin/non-steroidal anti-inflam-
matory drug use,36 have been identified, the interplay between 
these risk factors is complex. A greater understanding would 
permit targeted public health approaches to increase risk factor 
awareness in the general population, leading to reduced CRC 
incidence.37
RG2: Insufficient evidence on the precise contributions of genet-
ic, environmental and lifestyle factors, and in particular how they  
interact together to influence the risk of developing CRC.
Genetic risk factors for CRC
There is incomplete elucidation of CRC heritable risk factors, 
especially of polygenic risk (ie, where the contribution of 
multiple genes must be enumerated/quantified). Collabora-
tive initiatives such as GECCO (Genetics and Epidemiology 
of Colorectal Cancer Consortium)38 and GAME-ON (Genetic 
Associations and Mechanisms in Oncology Consortium)39 have 
significantly contributed to identification of risk-susceptibility 
loci.40–42 However, additional gene discovery initiatives are 
required, with increased concentration on evaluation of genetic 
risk in a broader diversity of populations/ethnic groups.43 44 
International data sharing collaboratives will be required, partic-
ularly to evaluate significance of rare genetic variants. Devel-
oping a gene panel for common CRC risk variants, mirroring a 
similar recently applied approach in breast cancer,45 may allow 
more precise delineation of CRC risk.
table 1 Critical RGs in colorectal cancer
Research area critical Rgs
Discovery science RG1: A need for realistic in silico, in vitro and in vivo models that more precisely recapitulate the tumour and its micro/macroenvironment, to enable 
comprehensive dissection of the relevant mechanisms governing the transition from normal colorectum to the different malignant stages of the 
disease.
Risk RG2: Insufficient evidence on the precise contributions of genetic, environmental and lifestyle factors, and in particular how they interact together, to 
influence the risk of developing CRC.
Prevention RG3: A need for intervention trials of preventive strategies addressing ‘dose’, timing, target group and acceptability, as well as mechanism of action.
RG4: Lack of interdisciplinary collaboration is undermining evaluation of real-life preventative interventions in CRC.
Early diagnosis and 
screening
RG5: Lack of an optimal strategy for screening for CRC.
RG6: Lack of an effective triage system for symptomatic patients that can determine who will benefit most from invasive investigation.
Pathology: diagnosis – 
prognosis – prediction
RG7: Imprecise pathological assessment of CRC is an unmet challenge.
RG8: Lack of qualified personnel to apply state-of-the-art knowledge in genomics, big data science and digital pathology.
Curative treatment RG9: Inadequate assessment and communication of risk, benefit and uncertainty of treatment choices where cure is possible.
RG10: A need for novel technologies/interventions that have the potential to improve curative outcomes.
Stage IV disease RG11: Lack of approaches that take cognisance of the molecular interplay between the metastasising tumour and its microenvironment and help 
guide evolution of innovative treatments that deliver improved health outcomes for the stage IV patient.
RG12: Lack of reliable prognostic and predictive biomarkers to help guide stage IV patient pathways.
Living with and beyond 
CRC
RG13: The need to increase understanding of health-related quality of life (HRQOL) issues and resolve residual symptoms as part of a research effort 
to enhance survivorship for those living with and beyond CRC.
Overarching RGs that need 
to be addressed
RG14: Lack of coordination of CRC research and its funding, leading to fragmented efforts to elucidate the biology of the disease and translate this 
knowledge into new preventative agents, screening tools, diagnostics and therapeutics.
RG15: Lack of effective communication strategies between healthcare professionals, patients with CRC/survivors, those at elevated risk of developing 
CRC, and the general public and varying levels of awareness of key risk factors, prevention options and benefits/risks associated with different 
treatment options.
CRC, colorectal cancer; RG, research gap.
 o
n
 27 February 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2017-315333 on 12 December 2017. Downloaded from 
182 Lawler M, et al. Gut 2018;67:179–193. doi:10.1136/gutjnl-2017-315333
Recent advances in clinical practice
RR2.1: Conduct comprehensive genetic susceptibility studies, sup-
ported by enabling data sharing platforms, in appropriately diverse 
human populations to maximise identification of genetic risks fac-
tors that have general applicability, or are relevant to specific ethnic 
populations.
Environmental/lifestyle contributions to CRC risk
There are significant environmental/lifestyle contributors to 
enhanced CRC risk. Increasingly, we require precise data-ana-
lytic tools to evaluate, assign and quantify gene-gene,46 gene-en-
vironment and gene-lifestyle risk.47 48 Recent studies have linked 
high-quality diets (assessed by diet quality indices) with low 
CRC risk in a multiethnic cohort,49 while a genome-wide diet–
gene interaction analysis indicated a novel association between 
processed meat consumption, a particular genetic variant and 
increased CRC risk.48 Studies have also investigated interactions 
between gene variants, smoking/alcohol consumption and risk 
of developing CRC.50 Ensuring the robustness of data-analytic 
methodologies and applying them to high-quality large data sets 
will help confirm current hypotheses, and identify novel nature–
nurture interactions for further modelling and testing in diverse 
populations and cohorts, to determine the universality of their 
ability to predict increased/reduced risk.
RR2.2: Develop robust data analytical tools that define and quanti-
fy the precise interplay between genetic and environmental/lifestyle 
factors to attributable CRC risk. 
Population-based assessment of CRC risk
International collaboration is continually cataloguing potential 
independent lifestyle risk indicators in population studies.34 
However, we need prospective high-quality pan-population 
studies of CRC risk factors, with complete ascertainment, accu-
rate longitudinal clinical and pathological data, and supporting 
blood/tissue samples. Collection of high-quality treatment 
response and toxicity data should also be mandated to help 
identify risk factors for relapse or treatment-related side effects. 
A national registry approach to managing risk may be the best 
way to identify an unbiased population set of high-risk patients. 
This should be linked to clinical networks, including national 
approaches to surveillance and screening, enabling development 
of enhanced prevention and surveillance programmes for high-
risk patients,51 and reallocation of valuable resources for those 
at low risk.52
RR2.3: Design and implement prospective high-quality pan-pop-
ulation studies of risk factors for CRC, with robust clinical/patho-
logical data, supporting blood and tissue samples, to inform a  
population-based assessment of risk.
Prevention
Current status
Despite widespread awareness that efforts to avoid CRC devel-
opment are critical,53 prevention research is under-represented 
in the CRC research portfolio. The UK NCRI funding in 2015 
for all cancers was £498 million, but only 3% was spent on 
prevention.54 The gap in CRC prevention research is particu-
larly notable in high-risk populations, such as patients with 
Lynch syndrome.55 The preventability estimate (World Cancer 
Research Fund) indicates that ~45% of CRCs are accounted 
for by lifestyle factors (dietary factors, obesity, lack of physical 
activity and alcohol consumption56). Dietary factors (low dietary 
fibre intake, high red/processed meat intake) are considered the 
main lifestyle area of concern.56 An evolving understanding of 
the gut microbiome and diet–microbial interactions has high-
lighted the potential for modulation of the diet-microbiome-me-
tabolome axis for cancer prevention.57
The global impact of obesity on cancer is significant, contrib-
uting to ~10% of the overall cancer burden in North America, 
Europe and the Middle East.58 This is reflected in a significant 
association between increasing body mass index (BMI) and 
CRC development.59 The International Agency for Research on 
Cancer recently convened a working group (WG) to assess body 
fatness and cancer risk. For CRC, their findings confirmed the 
association between increased BMI and CRC risk and indicated 
that a significant body of preclinical data supported a preven-
tative effect of calorific restriction;60 this should be actively 
pursued. Increased physical activity also has an important role in 
CRC prevention strategies.61
There is compelling evidence that chemopreventive interven-
tions such as aspirin55 62 63 in high-risk patients can be effective, 
prompting the US Preventive Services Task Force to recom-
mended its use in primary CRC prevention.64 However, compli-
cations, including GI bleeding, need to be considered, although 
the harm-versus-benefit ratio is frequently exaggerated.65 
Additionally, a recent study has indicated a lack of awareness 
of aspirin’s chemopreventive effects by >50% of primary care 
physicians surveyed,66 particularly for high-risk populations (eg, 
Lynch syndrome carriers), highlighting the need for appropriate 
education/guidance strategies. Many intervention trials (of diet, 
physical activity or chemoprevention) occur in the postdiagnosis 
setting—we need to ensure more CRC preventive trials which 
target specific high-risk populations with robust endpoints are 
conducted prior to CRC onset.
RG3: A need for intervention trials of preventive strategies address-
ing ‘dose’, timing, target group and acceptability, as well as mech-
anism of action.
RG4: Lack of interdisciplinary collaboration is undermining evalu-
ation of real-life preventative interventions in CRC.
Integrating dietary, lifestyle and chemopreventive interventions
There is an increasing need to reflect how interventions can 
be delivered in ‘real life’ (eg, combining screening, lifestyle 
interventions and chemoprevention), going beyond traditional 
discipline boundaries when designing efficacy and, particularly, 
effectiveness studies. New research models and transdisciplinary 
paradigms must be established in CRC prevention, perhaps in 
an approach analogous to NCI’s Transdisciplinary Research 
on Energetics and Cancer Initiative,67 which brought together 
expertise in behaviour, biostatistics, computer science, discovery 
science, endocrinology, engineering, epidemiology, genetics, 
health economics, medicine, nutrition and physical activity. We 
need multidisciplinary approaches to help define optimal ways 
to implement lifestyle change programmes. Another example 
is the microbiome,68 where our increased understanding of gut 
microbiota69 and their manipulation is highlighting how diet/
nutrient/physical activity-based interventional approaches can 
help prime the microbiome as a preventative agent.
RR3.1: Encourage transdisciplinary, multimodal approaches to 
CRC prevention, through cross-community collaboration.
The need for long-term studies
There is a dearth of studies which enable observational (and 
other) evidence to be tested robustly in long-term studies. Chal-
lenges include recruitment (due to incorrect perceptions about 
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disease prevention, particularly lifestyle interventions, and lack 
of HCP support), protocol implementation and adherence, and 
lack of appropriate endpoints. We need longer term analysis of 
robust interventions demonstrating feasibility and acceptability 
with promising indicative outcomes,70 which can then be tested 
in full-scale trials of relevant duration, with clinically relevant 
outcomes in at-risk patients.
RR3.2: Ensure future delivery of high-quality robust long-term 
studies that identify the appropriate level of intervention including 
dose, duration, timing, feasibility and acceptability as well as clini-
cally relevant outcome(s).
Ensuring coordination of intervention trials and research into 
barriers to uptake
Intervention trials and research into barriers to uptake of 
research findings and clinical impact must occur concurrently. 
We also need to break down current regulatory and funding 
hurdles to timely and cost-effective prevention research, particu-
larly for interventions employing off-licence drugs, undesignated 
drugs (eg, food supplements), or requiring human resource, 
for example, a counsellor/dietitian/trained volunteer/phys-
ical activity trainer. Stronger public involvement in evaluating 
optimal ways to promote more effective diet and lifestyle inter-
ventions, including the need to optimise teachable moments71 
should be encouraged.
RR4.1: Coordinate interventional trial activity to ensure maximum 
impact of precise and effective prevention strategies across the  
population.
Defining mechanism of action of selected interventions
A better understanding of mechanism(s) of action of prevention 
interventions is needed in order to define the most effective 
intervention, its timing and ‘dose’, as well as identifying indi-
viduals most likely to benefit. Intervention trials and observa-
tional cohorts could usefully include blood/tissue biobanks as 
key enablers of mechanistic research. Specific research calls 
for multimodal intervention studies should be developed with 
emphasis on effectiveness (including non-cancer secondary 
endpoints) and health economic outcomes.
RR4.2: Promote studies that help elucidate mechanism of action of 
prevention interventions.
RR4.3: Develop precise individual risk stratification approaches to 
ensure prevention interventions are employed most effectively.
early diagnosis and screening
Current status
Although colonoscopy is widely employed for screening asymp-
tomatic individuals in the USA, most countries have adopted a 
single biennial faecal immunochemical test (FIT) for blood in the 
stool for programmatic screening.72 As a population screening 
tool, colonoscopy is expensive, associated with low uptake and 
is potentially hazardous. FIT is easy to deliver and affordable in 
cost-limited or colonoscopy-limited settings, by simply adjusting 
the FIT sensitivity thresholds. High sensitivity from low FIT 
thresholds decreases specificity and test precision, leading to 
higher false-positive rates, increased patient anxiety and pressure 
on colonoscopy services.73 74
Population screening using a single flexible sigmoidoscopy 
(FS) has proven efficacy with reduced CRC incidence and 
mortality.75 FS at age 55 has been adopted by the English Bowel 
Screening Programme prior to guaiac-based Faecal Occult Blood 
Test at age 60. Limited FS resource and poor pathology yield in 
the age group chosen for the English programme may challenge 
the prospective clinical benefits observed in randomised clinical 
trials (RCT).
Early diagnosis by prompt recognition and reporting of symp-
toms by the public has been advocated, but to date has only 
succeeded in increasing rates of referral for investigation (usually 
colonoscopy), with no impact on rates of diagnosis of early 
disease.76 77 These initiatives have created increased pressure on 
diagnostic services; the need for effective triage of symptomatic 
patients is urgent. There is interest in the use of ‘low threshold 
FIT’ as an aid to decision-making.78 The National Institute for 
Health and Care Excellence has recently issued guidance recom-
mending highly sensitive FIT testing in patients with low-risk 
colorectal symptoms.79
Colonoscopy in population screening is being examined world-
wide, but mortality data will not be available for 10–15 years.80 
CT colonography is another screening modality, but pilot RCTs 
have yet to provide mortality data.81 82 Aside from expediting 
adoption of FS at an appropriate age(s), future developments in 
population screening include refining use of FIT by cost analysis 
of different thresholds, introduction of risk-adjusted screening 
with conventional or machine learning techniques and develop-
ment of new markers.
RG5: Lack of an optimal strategy for screening for CRC.
RG6: Lack of an effective triage system for symptomatic pa-
tients that can determine who will benefit most from invasive  
investigation.
Risk adjustment
The threshold of faecal haemoglobin concentration that triggers 
a colonoscopy can be adjusted to increase sensitivity.73 74 While 
modelling studies have assessed the cost-effectiveness of changes 
to the FIT threshold, RCTs would supplement these studies.
RR5.1: Embed research RCTs in FIT-based screening programmes 
to explore the optimal FIT threshold and/or the role of flexible 
sigmoidoscopy, incorporating risk adjustment algorithms.
Another approach to FIT-based risk assessment is to incor-
porate age, gender83 84 and participant’s screening history (eg, 
adherence to biennial screening, previous FS or colonoscopy, 
and so on, and other risk markers such as primary care blood 
results,85 BMI or smoking status). An alternative or additional 
approach is to vary the screening interval, depending on FIT 
concentration or concentration trends or more comprehensive 
risk scores which incorporate age, gender and specific symptoms.
New technologies
Several technologies including analysis of DNA from faecal 
samples86 and use of peripheral blood biomarkers such as meth-
ylated Septin 987 have not yet proven to be as clinically sensitive 
as FIT in population screening. Current developments include 
the detection of volatile metabolites in breath,88 use of liquid 
biopsies,89 the potential role of changes in the microbiome90 
and colon capsule endoscopy.91 These emerging technologies 
could be combined with morpho-molecular parameters if not 
for screening, then for risk stratification in early-stage disease 
and predicting disease recurrence.92 93
RR6.1: Establish accurate risk-based assessment of symptomatic 
patients, incorporating FIT and promising novel technologies.
RR6.2: Develop and trial sensitive and specific tests that could be 
employed in both screening and symptomatic services.
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Pathology: diagnosis–prognosis–prediction
Current status
The present gold standard to assign patients with CRC to prog-
nostic groups is the TNM (tumour, node, metastases) classifi-
cation.94 95 This anatomic staging approach frequently clusters 
patients with biologically different diseases and allows only 
approximate estimates of survival outcomes. Increasing the accu-
racy and reproducibility of morphological prognostic factors is 
therefore a major challenge for pathologists.96–98
Ongoing research promotes incorporation of an increasing 
number of molecular biomarkers into the CRC specimen 
reporting.99 Well-established elements include immunohis-
tochemistry testing of MMR protein expression, analysis of 
microsatellite instability and MLH1 promoter hypermethyl-
ation. Clinical next-generation sequencing can underpin the 
fast, reliable, broadly applicable and cost-effective detection 
of mutations for prognostication and prediction of response 
to targeted agents.100–102 Understanding the patient’s genetic 
context is also important for prognosis, treatment response and 
toxicity.103 104 Clinical success of immune-checkpoint inhibitor 
therapy in hypermutated CRC is driving the search for novel 
biomarkers to help stratify immunotherapy-based approaches.105 
Advances in gene expression profiling106–108 have culminated in 
a consensus molecular subtype classification,13 but its clinical 
value is currently unclear.
Overall, there is a critical need to revitalise CRC biomarker 
research, which has previously been limited by inconsistent 
methodologies and lack of reproducibility. Digital pathology, 
translational bioinformatics and machine learning must become 
critical components of modern pathology,109 integrating rapidly 
expanding clinical and laboratory data sets to underpin algo-
rithm development for risk prediction/disease stratification. This 
creates a presently unmet demand for large numbers of highly 
qualified personnel in the pathology sector.
RG7: Imprecise pathological assessment of CRC is an unmet  
challenge.
Risk stratification in early-stage disease
RGs are evident in the morphology-based risk stratification 
of colorectal precursor lesions and in clinical surveillance of 
patients with IBD. Although pathologists are mostly effective 
at diagnosing high-grade lesions, morphological categories are 
broad and interobserver reproducibility is limited.110 Translation 
of discovery research findings on the molecular pathogenesis of 
IBD-associated neoplasia will help improve utility and cost-ef-
fectiveness of screening approaches at the population level.
In stage I disease, most patients are cured by endoscopic polyp 
removal. However, up to 20% of cases may have occult nodal 
micrometastasis at time of resection.111 112 Stratification through 
assessment of additional histomorphological risk factors is heter-
ogeneously reported and prone to variable reproducibility.98 99 113 
Methodological standardisation and integration of biological 
data is needed to improve risk prediction in early-stage disease.
RR7.1: Precisely define the morpho-molecular taxonomy of pre-
cursor lesions and early-stage disease to help inform risk stratifi-
cation in CRC.
Predicting disease recurrence and treatment response
Better approaches to predict recurrence, therapy response and 
toxicity are required to guide personalised treatment of patients 
with CRC. Reliable identification of high-risk stage II patients is 
a presently unmet challenge.114–117 Most patients with stage III 
disease will receive standard chemotherapy or radiotherapy.118 
However, up to 70% will not relapse following potentially cura-
tive resection, derive no benefit from chemotherapy and suffer 
toxic side effects.119 In stage IV disease, there is a need for accu-
rate stratification for surgical treatment and early detection of 
evolving drug resistance. Further integration of genomic,102 
immune120 and transcriptomic approaches13–17 106–108 into patho-
logic tumour staging is a critical enabler for personalised treat-
ment of patients with CRC.
RR7.2: Develop new standardised molecularly informed multipa-
rameter algorithms to permit improved prediction of disease recur-
rence and therapy response.
Developing robust molecular signatures for precision pathology 
analysis
Molecular taxonomy studies have highlighted the important 
contribution of the stroma to CRC, and its association with poor 
prognosis disease.16 17 However, intratumoural heterogeneity, 
due to variations in stromal content,15–18 can compromise clin-
ical application of molecular profiling. The recent discovery of 
a CRC intrinsic signature14 may have more robust prognostic/
predictive relevance,15 and should be considered for inclusion 
in molecular pathology workflows. A key enabling technology 
is the improved analysis of formalin-fixed paraffin-embedded 
tissues (and alternative non-formalin-based fixatives), given the 
logistical challenges with use of fresh-frozen tissue.
RR7.3: Use our evolving understanding of the CRC tumour and 
its microenvironment to underpin standardised approaches for pa-
thology specimen analysis.
Growing the talent pool and skilling the pathology workforce
Genomic medicine is given limited space in medical curricula 
and pathology training. Know-how in digital image anal-
ysis, bioinformatics and machine learning is currently lacking, 
compromising development and application of next-generation 
diagnostic tools. Pathologists are thus at risk of losing their meth-
odological competence to lead, evaluate and guide biomarker 
testing in personalised medicine and biomedical research.
RG8: Lack of qualified personnel to apply state-of-the-art knowl-
edge in genomics, big data science and digital pathology.
The UK government’s life sciences strategy lists molecular 
diagnostics, digital pathology and artificial intelligence as key 
strategic areas for further development.121 Structured educa-
tional programmes in genomics/bioinformatics should be offered 
to complement existing training. Exemplary efforts to promote 
genomic pathology education have been made (eg, Health 
Education England’s Medical Genomics Programme (UK)122; 
Training Residents in Genomics Working Group (USA)).123 A 
network approach in conjunction with national/international 
pathological societies is warranted to advance learning for the 
present and future workforce. Funded programmes should be 
established to encourage collaboration of histopathologists with 
molecular geneticists, bioinformaticians and physical scientists 
to establish optimal methodologies of data accumulation/inte-
gration, thus retooling and empowering the emerging molecular 
pathology generation.
RR8.1: Embed interdisciplinary education/training within un-
dergraduate/postgraduate and continuing professional educa-
tion curricula to ensure recruitment, retention and upskilling of  
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qualified personnel to deliver modern pathology to the CRC com-
munity.
curative treatment
Current status
Recent technological advances have improved the quality of cura-
tive therapies: the advent, evaluation and widespread adoption 
of laparoscopic colorectal surgery, for example, have improved 
short-term recovery at no expense to survival.124 125 However, 
there are significant regional variations in the delivery of certain 
innovations because of a lack of definitive research studies.126
Cure is becoming increasingly feasible, but effective 
patient-centred care requires consideration of broader treatment 
effects. Patients with advanced disease may have access to novel 
therapies with only limited survival benefits but which cause 
major morbidity. Similarly, patients with very ‘curable’ disease 
may want to explore treatment options with reduced chance 
of cure but minimal impact on health-related quality of life 
(HRQOL).127 Current research continues to investigate treat-
ments that minimise toxicity (SCOT and IDEA trials)128 129 or 
amplify survival for patients undergoing established treatments 
(eg, ADD-ASPIRIN, CHALLENGE and FOxTROT trials).130–132
RG9: Inadequate assessment and communication of risk, benefit 
and uncertainty of treatment choices where cure is possible.
RG10: A need for novel technologies/interventions that have the po-
tential to improve curative outcomes.
Informing shared decision-making
Great advances have been made in understanding, implementing 
and optimising patient-centred care;133 however, further work is 
needed to address the specific issues in new and evolving CRC 
therapies. Appropriate research, answering key questions that 
inform shared decision-making, must be conducted.
It is now accepted, for example, that definitive radiotherapy 
and organ preservation may be a viable alternative to major resec-
tional surgery.134 135 Communicating the balance between patient 
experience and maximising survival in rectal cancer is extremely 
relevant. A non–surgical approach may lead to better HRQOL 
but with a reduced chance of cure, while a major surgery has 
greater immediate risks, but may have a higher chance of cure.
RR9.1: Develop an appropriate evidence base to inform shared  
decision-making for potentially curative therapies for patients.
Establishing optimum peritherapeutic interventions
Critical to shared decision-making is anaesthetic risk assess-
ment136 but currently there remain limitations in tools that give 
us a valid risk assessment for more frail patients and/or those 
with significant comorbidities.137 Mitigating risk or optimally 
reducing its impact is a vital component in improving outcomes. 
We need to improve pre/post/perioperative management to 
enhance patient experience (both short term and long term) and 
survival after ‘curative therapies’.
RR10.1: Establish optimum peritherapeutic interventions to im-
prove curative outcomes.
Optimising health-preserving benefit in metastatic/recurrent disease
We have continued to push the boundaries of curative interven-
tions in CRC.138 Selecting an individual for potentially more 
aggressive approaches when the disease has spread beyond 
the confines of the bowel has become commonplace, but each 
time we extend these boundaries, further evaluation to fill our 
knowledge gap is required. Specifically, questions arise such as: 
‘How should we select patients for novel curative therapeutic 
interventions for oligometastatic disease?’, ‘What is the role of 
ablative technologies for cure in metastatic disease?’ and ‘What 
is the evidence for highly aggressive surgical intervention for 
recurrent/locally advanced disease?’
RR10.2: Optimise curative approaches for metastatic or recurrent 
disease that balance patients’ expectations with treatment efficacy 
and health-preserving benefit.
Biomarkers for optimal treatment selection
Broad technological advances have been made in CRC therapy 
including surgery, radiotherapy and molecular-based treat-
ment.139–141 These advances may impact upon existing therapeutic 
options, for example, by optimising the use of chemotherapies 
in the adjuvant setting to avoid excessive toxicities, or by under-
pinning newer biomarker-driven treatment selection. This aims 
to move beyond the standard of care to a more individualised 
approach.
RR10.3: Develop biomarkers that define the optimal curative ther-
apeutic strategy for an individual or group, preventing overtreat-
ment and improving treatment selection.
New methodologies
Methods to ensure optimal evaluation of new surgical and 
radiotherapy-related devices and procedures142 143 are needed 
to demonstrate appropriately robust clinical and cost-effective 
outcomes. Such methods have been promoted by the IDEAL 
(Idea, Development, Exploration, Assessment, Long-term 
follow-up) collaboration,144 but further methodological devel-
opment is needed, particularly in early phase studies. This will 
promote consistency in standard therapeutic pathway develop-
ment, ensuring that the best therapies are more widely used, 
based on compelling evidence at an earlier stage. It is critically 
important to define the interventions to be tested, but equally 
important are methodologies for their evaluation, providing the 
evidence base to encourage their integration into clinical prac-
tice to enhance curative outcomes.
RR10.4: Develop research methodologies to optimally evaluate 
new curative approaches.
stage Iv disease
Current status
Around 20% of patients presenting with CRC have metastatic 
disease (mCRC) at time of diagnosis.145 A further 20%–25% will 
develop mCRC during follow-up after initial curative intent 
treatment of their primary tumour. Recently, there has been an 
expansion in the range of modalities available for treating stage 
IV CRC. More aggressive approaches to resection of mCRC 
(particularly major liver resection), combined with ablative tech-
nologies and loco-regional treatments, are allowing potentially 
curative options to be offered to more patients. For chemo-
therapy, the single agent (5-fluorouracil) available 20 years ago 
has multiplied into 13 available drugs in 2016.146 Despite these 
incremental advances in patient treatment, disease cure remains 
unattainable for many.
Genomic technologies have given valuable insights into CRC 
heterogeneity, leading to identification of distinctive molec-
ular subtypes.13–15 Knowledge of the associated clinical rami-
fications of these subtypes should help optimise treatment 
strategies. Recent advances in immunotherapy have resulted 
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in significant clinical benefit in non-small cell lung cancer and 
melanoma.147–149 We need to translate these successes into new 
treatment approaches in CRC, beyond the benefit already seen 
with immune-checkpoint inhibition in the ~5% of patients with 
metastatic disease whose tumours have deficient DNA MMR.150
RG11: Lack of approaches that take cognisance of the molecular 
interplay between the metastasising tumour and its microenviron-
ment and help guide evolution of innovative treatments that deliver 
improved health outcomes for the stage IV patient.
Multimodality treatment in stage IV disease
There have been major developments in surgical resection of 
both primary and metastatic diseases, with advanced techniques 
permitting radical resection.151 However, fundamental questions 
remain unanswered such as whether primary tumour resection 
in the presence of synchronous inoperable metastatic disease 
affects the natural history of the disease. It is now possible to 
perform radical peritonectomies and major pelvic exenterations 
for primary and recurrent disease,152 153 but significant varia-
tions in practice from preoperative imaging through to clinical 
intervention remain. Understanding which patients to select for 
which procedure is challenging, and outcome data, including 
increasingly relevant long-term patient-reported outcome 
measures (PROMs) are not robust.
Minimally invasive surgical techniques are being evaluated in 
mCRC management,154 and in the UK a trial is open comparing 
resection and percutaneous ablation in operable liver metas-
tases.155 Disappointingly, the initial promise observed in trials 
investigating radioembolisation in patients with inoperable liver 
metastases has not translated into improved overall survival.143 
Currently, only patients with low-burden, circumscribed metas-
tases are potentially curable. Consensus guidelines on the 
sequence, setting (eg, supraregional centres for certain aspects of 
care) and timing of multimodality treatment, including systemic 
therapy to downsize inoperable disease, would translate into 
more patients being cured, including those with multisite meta-
static disease. Even in non-curable disease, the role of multi-
modality therapy combining downstaging systemic therapies, 
resection and ablation of the majority of multiorgan mCRC, may 
allow prolonged survival with good HRQOL and freedom from 
symptoms. This concept of ‘optimal debulking’, based on clinical 
practice in ovarian cancer, is now being investigated in CRC, in 
clinical trials such as ORCHESTRA,156 and should be explored 
more widely.
RR11.1: Develop evidence-based approaches utilising multimodal-
ity treatment for patients with stage IV CRC to maximise the utility 
of cutting-edge technologies to improve outcomes.
RG12: Lack of reliable prognostic and predictive biomarkers to help 
guide stage IV patient pathways.
Stratification of patients
The lack of widely accepted prognostic and predictive 
biomarkers results in limited consensus to guide stage IV patient 
pathways. For example, how should we adopt WES/whole-ge-
nome sequencing into our standard of care and how do we 
interpret and transmit large-scale multiomics data for clinical 
decision-making? Transcriptomic analysis is starting to yield clin-
ically relevant results which can help inform molecular stratifi-
cation of patients with CRC to improve outcomes. Trials such as 
FOCUS-4, a multistage multiarm approach in CRC, may provide 
the appropriate model going forward.157 An important consid-
eration is the increasing age of the population, as more frail 
patients with complex medical needs are diagnosed. Accurately 
recognising and understanding which aspects of patient frailty 
are reversible (and potentially be amenable to prehabilitation) 
remains challenging.
RR12.1: Establish robust prognostic and predictive biomarkers to 
stratify patients to ensure every patient receives ‘bespoke’ treat-
ment, relevant to their particular disease course.
Understanding the microenvironment to help develop innovative 
treatments
Colon carcinogenesis occurs within an inflammatory microen-
vironment where gut bacteria provide constant immune stim-
ulation. Therefore, many immunosuppressive processes have 
been developed in colonic epithelium to prevent these bacte-
ria-induced inflammatory triggers.158 Interplay between the gut 
microbiome, inflammation and carcinogenesis is complex but is 
critical to understand to improve CRC treatment.
CRC stem cells play a significant role in intratumoural hetero-
geneity.159 As a dynamic population of cells, they respond to 
genetic and epigenetic factors along with microenvironmental 
signals to influence key processes such as metastatic potential 
and chemotherapy resistance. CRC cells can thus continuously 
adapt to their environment, highlighting the difficulty of devel-
oping suitable models to target cancer stem cells by directed 
therapies.
To date, despite significant efforts, immune-mediated 
approaches in CRC have had limited success. High gene muta-
tional load160 and the presence of DNA MMR deficiency and 
DNA polymerase E proofreading mutations150 161 correlate with 
improved outcomes to immune-checkpoint inhibitors. Immuno-
score is a scoring system based on quantifying the number of 
cytotoxic and memory T cells infiltrating the core and leading 
edge of the tumour.97 162 Using this approach may allow iden-
tification of a prognostic biomarker of responsiveness to 
immune-checkpoint inhibitors. Significant work is ongoing to 
understand how the role of the microenvironment (including 
the gut microbiome) influences immune-evading mechanisms 
or immune-editing in CRC,163 and this should help unlock the 
potential of immunotherapy in this disease.
RR12.2: Employ our evolving understanding of the role of the tu-
mour microenvironment in CRC to develop innovative therapies 
that modulate the microenvironment for clinical benefit.
living with and beyond cRc
Current status
Congruent with prioritisation of research to promote effective 
prevention, enable earlier more precise diagnosis and deliver 
optimal treatments to enhance CRC outcomes, there is a need 
for more research-informed approaches to improve HRQOL 
and enhance survivorship for the expanding population now 
living with and beyond CRC. Instruments such as the EORTC 
QLQ-CR29 questionnaire are invaluable in assessing HRQOL 
in CRC,164 while the recently introduced ESMO Magnitude of 
Clinical Benefit Scale165 includes HRQOL in its evaluation of 
benefit/value of new treatments. Despite this progress, there 
are still substantial gaps in our knowledge about optimising 
HRQOL; thus further research is required to inform appropriate 
intervention(s) and promote a responsive HRQOL agenda for 
the CRC survivor over the coming decade.
RG13: The need to increase understanding of health-related quali-
ty of life (HRQOL) issues and promote their resolution as part of 
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a research effort to enhance survivorship for those living with and 
beyond CRC.
Health-related quality of life
A recent systematic review indicated that >75% of reported 
studies addressing HRQOL in CRC were of inadequate meth-
odological/reporting quality.166 Additionally, many HRQOL 
studies are retrospective; introduction of preplanned analyses 
would significantly enhance data quality,167 and identify those 
patients who might benefit from early discontinuation of induc-
tion therapy or continuation/de-escalation of active maintenance 
treatment. Immune-checkpoint targeting is an exciting new ther-
apeutic modality, with unparalleled efficacy in MMR-deficient 
CRC,105 160 161 but knowledge of both short-term and long-term 
HRQOL issues and PROMs are limited. More precise research 
is also required to improve understanding of the psychological 
consequences (eg, emotional reactions, survivorship guilt, lack 
of reintegration into normal life) and social challenges (eg, 
employment, self-esteem, discrimination) for those living with 
and beyond CRC. Development of evidence-based models that 
elucidate relevant predictors of HRQOL168 would help pinpoint 
individuals at risk and provide potential solutions to help resolve 
the clinical/psychosocial sequelae of CRC and their treatment.
RR13.1: Precisely characterise the landscape of HRQOL sequelae 
in patients living with and beyond CRC, including those in receipt 
of novel treatment approaches (eg, immunotherapy).
Symptom management
A high proportion of patients have troublesome, embarrassing 
and potentially disabling symptoms after surgery/radiotherapy 
for CRC. Many patients experience a permanent change in bowel 
habit after anterior rectal resection (AR),169 with major nega-
tive impacts on daily living.170 171 A meta-analysis of >3300 AR 
patients has found a 35% incidence of faecal incontinence 
(FI).172 Following pelvic radiotherapy, GI symptoms are the most 
common chronic side effect, with 50% of patients reporting 
significant effects on HRQOL.173 Chronic FI frequently occurs 
after radiotherapy for rectal cancer.173
Published systematic reviews have found remarkably few 
intervention studies and no RCTs in patients with anterior resec-
tion syndrome.174–176 Hyperbaric oxygen has frequently been 
used to treat patients following pelvic radiotherapy, but a recent 
RCT demonstrated no benefit, highlighting the urgent need for 
new approaches.177 After radiotherapy, it is possible to improve 
symptoms with relatively low-cost interventions,178 179 but 
studies of lifestyle interventions, self-management and choice of 
optimal support services are lacking.
We need to better understand which aspects of treatment cause 
symptoms and define their underlying mechanism, in order to 
test measures to prevent/ameliorate symptom development and 
treat symptoms when they are troublesome.
RR13.2: Elucidate the causes of symptoms following CRC treat-
ment and develop viable solutions for their prevention and/or man-
agement.
Lifestyle interventions
Emerging evidence suggests that lifestyle interventions 
promoting increased physical activity,180 healthy eating181 and 
weight control can have significant benefits, but research on 
their impact following CRC treatment or during recurrence is 
limited.182 183 More longitudinal studies are required to underpin 
the evidence base for introduction of such interventions and to 
identify appropriate tools to measure their proposed benefits.184
RR13.3: Evaluate the evidence base and impact of lifestyle inter-
ventions, including increased physical activity and better nutrition 
in CRC.
Survivorship
Survivorship care planning must involve meaningful two-way 
dialogue. However, surveys reveal that only a minority of HCPs 
regularly discuss survivorship issues or provide survivorship 
care plans to those living beyond CRC.185 186 It is imperative 
to implement research-informed National Cancer Survivorship 
Plans.187–189 Research to develop appropriate CRC survivorship 
care guidelines190 can underpin creation of relevant tools to 
nurture open and effective interactions between HCPs and CRC 
survivors, empowering a shared decision-making culture.
RR13.4: Develop research to support survivorship care planning 
and promote shared decision-making for people living with and 
beyond CRC.
Overarching Rgs that need to be addressed
In addition to the thematic RGs outlined above, there are also 
several cross-cutting RGs raised by a number of the WGs.
RG14: Lack of coordination of CRC research and its funding, lead-
ing to fragmented efforts to elucidate the biology of the disease and 
translate this knowledge into new preventative agents, screening 
tools, diagnostics and therapeutics.
The need for a national cancer research forum
Congruent with the multidisciplinary team approach delivering 
optimal care to patients with CRC is the need to bring together 
the diverse expertise increasingly required to answer the complex 
research challenges outlined in this paper. Linking biologists, 
physical scientists and mathematicians can fuel development of 
testable chemoprevention models. Integrating epidemiological, 
bioinformatic, pathological and clinical expertise can underpin 
rational biomarker-informed clinical trial design. Capturing all 
of this expertise under the umbrella of a national CRC research 
conference in the UK, for example, would provide the impetus 
for a coordinated interdisciplinary approach to successfully 
address the critical challenges in CRC research.
RR14.1: Establish an annual national multidisciplinary CRC re-
search conference that draws together the entire CRC community 
in a coordinated research effort.
The need for data sharing
A recurrent theme from a number of the WGs was the need to 
provide mechanisms and tools that enable sharing of the ever-ex-
panding data outputs generated through CRC research. Sharing 
of genomic, clinical, epidemiological and lifestyle data can be 
challenging, but international collaborative efforts such as the 
Global Alliance for Genomics and Health191 provide a blueprint 
for effective but responsible data sharing in cancer that addresses 
the technical, ethical, legal and security barriers.192 193 Devel-
opment of bespoke data-analytic platforms,194 tailored to the 
requirements of the CRC community, could maximise the value 
of the rich sources of data being generated and yield significant 
benefits for CRC researchers, patients and society.
 o
n
 27 February 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2017-315333 on 12 December 2017. Downloaded from 
188 Lawler M, et al. Gut 2018;67:179–193. doi:10.1136/gutjnl-2017-315333
Recent advances in clinical practice
RR14.2: Develop bespoke data-analytic platforms that maximise 
the value of CRC genomic, clinical, epidemiological and lifestyle 
data.
Prioritising funding for CRC research
As well as prioritising research activity, the BCUK’s Critical 
Research Gaps in Colorectal Cancer Initiative provides an excel-
lent opportunity for research funders (eg, research councils, 
cancer charities, non-governmental organisations) to concen-
trate their funding in particular areas of focus where there is 
a defined research need, and/or investigate the potential for 
collaborative research grant calls between complimentary 
research funding organisations. An example of this approach is 
the Medical Research Council-CRUK jointly funded Stratified 
Medicine in Colorectal Cancer consortium,157 195 which brings 
together diverse stakeholders in a research collaborative to 
develop predictive and prognostic markers that drive precision 
medicine approaches in CRC.
RR14.3: Prioritise research resource allocation to recognise re-
search gaps and encourage collaborative research grant calls be-
tween complimentary research funding organisations.
RG15: Lack of effective communication strategies between health-
care professionals, patients with CRC/survivors, those at elevated 
risk of developing CRC, and the general public and varying levels of 
awareness of key risk factors, prevention options and benefits/risks 
associated with different treatment options.
Closing the communication gap
There are distinct challenges around CRC health literacy and 
communication between HCPs and patients with CRC/survivors, 
those at elevated risk of developing CRC and the general public. 
Patients are becoming increasingly empowered to make their 
own personalised health decisions; this should be encouraged 
and nurtured. However, awareness of personal CRC risk/risk 
factors,196 197 appropriate prevention options198 and benefits/
risks associated with treatments199 is variable. Patient-adapted 
educational materials and shared decision-making tools200 201 
must be made available, empowering individual choice while 
facilitating formal assessment of ‘what is or was the right choice’ 
for that individual.
RR15.1: Development of patient and person-adapted educational 
materials and shared decision-making tools in order to empower 
individual choice.
Research into the most appropriate communication strategies 
for explaining risk and benefit in different settings (eg, cancer 
risk modification, surgery, adjuvant therapy) is crucial. Recent 
work on knowledge of, and attitudes to, CRC chemoprevention 
has highlighted that a majority of primary care physicians were 
unaware of the chemopreventive properties of aspirin.202 There 
is a need for better communication with patients about treat-
ment-related symptoms, emphasising that it is legitimate to seek 
help (and not simply accept treatment-related complications as 
the price of a successful cure) and investigate both professionally 
led and self-help interventions.
From a patient communication perspective, PROMs play a key 
role in identifying specific needs, while also providing important 
information on outcomes.203 However, there are major varia-
tions in how PROMs are measured and employed.204 Studies 
should identify which PROMs best reflect the views/experiences 
of individuals living with and beyond CRC, and how they may 
signpost early indicators of disease recurrence.
Evidence is also required as to whether long-term access to 
a CRC nurse or other relevant HCP improves communication 
and shared decision-making, empowering survivors as active 
participants in their own care.205 A better understanding of why 
patients with CRC do or do not participate in RCTs would help 
facilitate recruitment and allow development of RCT protocols 
more relevant/acceptable to patients.206 A recent multinational 
survey indicated a high awareness of patients with breast, lung 
or CRC regarding the potential of precision medicine to deliver 
personalised care,207 but highlighted important regional varia-
tions and the patient’s need for additional information.
RR15.2: Embedding strategies that ensure appropriate communi-
cation of risk and benefit and best capture patient-reported out-
come measures (PROM) in order to ensure optimal outcomes for 
patients, their families and carers, and those at risk of developing 
CRC.
Research addressing these diverse communications issues can 
help ensure that patients with CRC/survivors and those at risk of 
developing CRC receive optimal information and participate in 
their health-preserving decisions as equals.
cOnclusIOns
In this position paper, we present the informed considerations 
of a wide-ranging multidisciplinary group of experts from 
UK-based research institutions, complemented by significant 
input from those affected by CRC. We articulate their collec-
tive viewpoint in a series of critical RGs and RRs (see online 
supplementary table 1), which if appropriately implemented 
would significantly impact on the prevention, early diagnosis, 
treatment and improved quality of life for people living with and 
beyond CRC. Prioritisation of CRC research activity, supported 
by effective policy decisions and appropriate resource alloca-
tions, will help us tackle this life-threatening, debilitating disease 
that kills ~800 000 of our citizens globally each year.
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